Cargando…
Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort
BACKGROUND: Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) play important roles in the turnover of extracellular matrix and in the pathogenesis of idiopathic pulmonary fibrosis (IPF). This study aimed to determine the utility of circulating MMPs and TIMPs in distinguishing pa...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071646/ https://www.ncbi.nlm.nih.gov/pubmed/32171287 http://dx.doi.org/10.1186/s12890-020-1103-4 |
_version_ | 1783506249591029760 |
---|---|
author | Todd, Jamie L. Vinisko, Richard Liu, Yi Neely, Megan L. Overton, Robert Flaherty, Kevin R. Noth, Imre Newby, L. Kristin Lasky, Joseph A. Olman, Mitchell A. Hesslinger, Christian Leonard, Thomas B. Palmer, Scott M. Belperio, John A. |
author_facet | Todd, Jamie L. Vinisko, Richard Liu, Yi Neely, Megan L. Overton, Robert Flaherty, Kevin R. Noth, Imre Newby, L. Kristin Lasky, Joseph A. Olman, Mitchell A. Hesslinger, Christian Leonard, Thomas B. Palmer, Scott M. Belperio, John A. |
author_sort | Todd, Jamie L. |
collection | PubMed |
description | BACKGROUND: Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) play important roles in the turnover of extracellular matrix and in the pathogenesis of idiopathic pulmonary fibrosis (IPF). This study aimed to determine the utility of circulating MMPs and TIMPs in distinguishing patients with IPF from controls and to explore associations between MMPs/TIMPs and measures of disease severity in patients with IPF. METHODS: The IPF cohort (n = 300) came from the IPF-PRO Registry, an observational multicenter registry of patients with IPF that was diagnosed or confirmed at the enrolling center in the past 6 months. Controls (n = 100) without known lung disease came from a population-based registry. Generalized linear models were used to compare circulating concentrations of MMPs 1, 2, 3, 7, 8, 9, 12, and 13 and TIMPs 1, 2, and 4 between patients with IPF and controls, and to investigate associations between circulating levels of these proteins and measures of IPF severity. Multivariable models were fit to identify the MMP/TIMPs that best distinguished patients with IPF from controls. RESULTS: All the MMP/TIMPs analyzed were present at significantly higher levels in patients with IPF compared with controls except for TIMP2. Multivariable analyses selected MMP8, MMP9 and TIMP1 as top candidates for distinguishing patients with IPF from controls. Higher concentrations of MMP7, MMP12, MMP13 and TIMP4 were significantly associated with lower diffusion capacity of the lung for carbon monoxide (DL(CO)) % predicted and higher composite physiologic index (worse disease). MMP9 was associated with the composite physiologic index. No MMP/TIMPs were associated with forced vital capacity % predicted. CONCLUSIONS: Circulating MMPs and TIMPs were broadly elevated among patients with IPF. Select MMP/TIMPs strongly associated with measures of disease severity. Our results identify potential MMP/TIMP targets for further development as disease-related biomarkers. |
format | Online Article Text |
id | pubmed-7071646 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-70716462020-03-18 Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort Todd, Jamie L. Vinisko, Richard Liu, Yi Neely, Megan L. Overton, Robert Flaherty, Kevin R. Noth, Imre Newby, L. Kristin Lasky, Joseph A. Olman, Mitchell A. Hesslinger, Christian Leonard, Thomas B. Palmer, Scott M. Belperio, John A. BMC Pulm Med Research Article BACKGROUND: Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) play important roles in the turnover of extracellular matrix and in the pathogenesis of idiopathic pulmonary fibrosis (IPF). This study aimed to determine the utility of circulating MMPs and TIMPs in distinguishing patients with IPF from controls and to explore associations between MMPs/TIMPs and measures of disease severity in patients with IPF. METHODS: The IPF cohort (n = 300) came from the IPF-PRO Registry, an observational multicenter registry of patients with IPF that was diagnosed or confirmed at the enrolling center in the past 6 months. Controls (n = 100) without known lung disease came from a population-based registry. Generalized linear models were used to compare circulating concentrations of MMPs 1, 2, 3, 7, 8, 9, 12, and 13 and TIMPs 1, 2, and 4 between patients with IPF and controls, and to investigate associations between circulating levels of these proteins and measures of IPF severity. Multivariable models were fit to identify the MMP/TIMPs that best distinguished patients with IPF from controls. RESULTS: All the MMP/TIMPs analyzed were present at significantly higher levels in patients with IPF compared with controls except for TIMP2. Multivariable analyses selected MMP8, MMP9 and TIMP1 as top candidates for distinguishing patients with IPF from controls. Higher concentrations of MMP7, MMP12, MMP13 and TIMP4 were significantly associated with lower diffusion capacity of the lung for carbon monoxide (DL(CO)) % predicted and higher composite physiologic index (worse disease). MMP9 was associated with the composite physiologic index. No MMP/TIMPs were associated with forced vital capacity % predicted. CONCLUSIONS: Circulating MMPs and TIMPs were broadly elevated among patients with IPF. Select MMP/TIMPs strongly associated with measures of disease severity. Our results identify potential MMP/TIMP targets for further development as disease-related biomarkers. BioMed Central 2020-03-14 /pmc/articles/PMC7071646/ /pubmed/32171287 http://dx.doi.org/10.1186/s12890-020-1103-4 Text en © The Author(s). 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Todd, Jamie L. Vinisko, Richard Liu, Yi Neely, Megan L. Overton, Robert Flaherty, Kevin R. Noth, Imre Newby, L. Kristin Lasky, Joseph A. Olman, Mitchell A. Hesslinger, Christian Leonard, Thomas B. Palmer, Scott M. Belperio, John A. Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort |
title | Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort |
title_full | Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort |
title_fullStr | Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort |
title_full_unstemmed | Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort |
title_short | Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort |
title_sort | circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter ipf-pro registry cohort |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071646/ https://www.ncbi.nlm.nih.gov/pubmed/32171287 http://dx.doi.org/10.1186/s12890-020-1103-4 |
work_keys_str_mv | AT toddjamiel circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort AT viniskorichard circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort AT liuyi circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort AT neelymeganl circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort AT overtonrobert circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort AT flahertykevinr circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort AT nothimre circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort AT newbylkristin circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort AT laskyjosepha circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort AT olmanmitchella circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort AT hesslingerchristian circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort AT leonardthomasb circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort AT palmerscottm circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort AT belperiojohna circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort AT circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort |